Caithness mountain rescue hero helping save lives despite terminal illness says 'MBE is something to leave behind to my wife'
At 4,400 metres up, Charlie MacLeod was stranded atop the summit of the Matterhorn with his climbing partner dead just below him and no rope to help him down.
It was his darkest moment, stuck in the heart of the Swiss Alps in the dead of winter, with no choice but to wait for a mountain rescue helicopter to bring him to safety.
But, it was also the day on which he decided on a life of helping others – often those experiencing their darkest day, as Charlie once did.
It's four decades since he made that decision and Charlie has since dedicated more than 15 years to Scottish Mountain Rescue (SMR) and the Search and Rescue Dog Association (SARDA).
His work has seen him navigate 'countless' rescues, from quick extractions to exhausting nine-day operations.
Mr MacLeod, of Ulbster in Caithness, continues to help save lives to this day as a staff trainer at SMR and a dog trainer at SARDA – even while battling a terminal prostate cancer diagnosis.
He was given the news two years ago and is currently receiving radium treatment at Raigmore Hospital.
Mobility issues and bouts of severe pain mean he is not scaling mountains any more – but he still provides a crucial service to as a staff trainer.
His ongoing service has seen him included on the King's Birthday Honours list – in which he has been made an MBE.
'It was a massive surprise, I wasn't expecting it at all,' he told us.
'I'm more proud than anything – the fact that the folk in the team thought I was worthy and nominated me.
'They do all the hard work and I'm more proud for them more than anything else.
'It is nice, but we don't do what we do for awards. We just want to help people.'
Mr MacLeod joined the Assynt Mountain Rescue Team in October 2009, having met the team while he raised funds for Alzheimer's charities and Aberdeen Mountain Rescue at a sponsored walk that year.
Before that he had spent more than 20 years working as a physiotherapist in Stirling.
Spurred on by his own rescue experience back in the 80s, he joined up with the team to 'repay the favour'.
He said it had been a 'privilege' to give back to those who saved his life all those years ago.
Charlie said: 'I was rescued myself a long time ago.
'I did the North Face of the Matterhorn in winter and my mate was killed just below the summit.
'We had no rope to descend either because we lost it.
'I had to get helicoptered off the top of the mountain, so I know what it's like to be rescued.
'I wanted to be able to repay that. And to be able to do that throughout my career has been a privilege really.
'Bad things can happen to anybody and so it's nice to be able to help people who are having a really bad day.
'I think most people in the mountain rescue are the exact same.'
Charlie said the 'extreme' situation he found himself in gives him a unique perspective on rescuing, and serves as motivation for the job.
He continued: 'I want to help people who have had a bad day. That's my motivation.
'We just want to do our best for these people.
'At it's core, it's just being there for people when they are in need.'
Charlie has been the team's training officer since 2013, passing on his skills, particularly in the area of avalanche risks.
His roles have seen him respond to many call outs, as a team member or dog handler, undertaking numerous multi-day searches and going 'above and beyond' to bring loved ones home all across Scotland.
Even with the immense challenges presented by his terminal cancer diagnosis, he is still made to feel 'part of the team' at SMR and SARDA.
He added that being part of that team has helped him get this far, through the gruelling cancer treatments.
Charlie tells me: 'My situation is a bit unique.
'I currently have terminal prostate cancer, but the mountain rescue teams and SARDA have just been so fantastic with me.
'They have been so good in supporting me, because my mobility is now severely limited.
'I am so proud to be a part of an organisation like that.'
He added: 'Even through my end of life care, they have allowed me to still feel needed and important and still feel I have lot to offer in terms of the training.
'It has been tough. I'm in a lot of pain and more recently my treatments are failing.'
Charlie concedes that his time 'is now limited,' but hopes that this MBE will give his wife Liz something to cherish after he is gone.
'It is going to be something really special that I can share with my wife Liz, to give her something to remember and hang on to.
'That means the world to me'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
a day ago
- Times
My brother died at 33 — what I wish I'd known
I remember seeing the troubling spark of recognition in the psychologist's eyes when I told her that my late brother, Charlie, had schizophrenia. We were sitting in her office going through a never-ending pile of forms as part of my seven-year-old son Eddie's autism-assessment process, including my family history. 'Did you know,' she asked, 'that autism used to be known as childhood schizophrenia?' I remember the grating rough texture of the chair I was sitting on prickling against the back of my legs and feeling the inside of my stomach flip. We lost my big brother, Charlie, in 2004 when he was 33 and he hadn't had a particularly happy life. He had been diagnosed with schizophrenia at the age of 18 after a period of psychosis — he had been hearing voices and became convinced that a group of people were out to get him.
Rhyl Journal
a day ago
- Rhyl Journal
Prestatyn grandmother ‘not given medication' for 20 days
Marion Yates, of St Chamond's Care Home, Hillside in Prestatyn, died aged 87 at the nursing home on January 2, 2025. At the resumption of the inquest into her death, held in Ruthin today (June 20), John Gittins, senior coroner for North Wales East and Central, gave a medical cause of death of a chest infection with contributing Alzheimer's and a stroke. Mrs Yates was born in Atherton, Manchester on June 10, 1937, and was widowed, a mother to three sons and a retired business owner. The inquest was told Mrs Yates had been 'very active throughout her life', and was a 'great mum' who had worked for British Coal, in finance, and had run a successful newsagent in Fleetwood twice. Her son told the inquest that she had 'loved baking, loved making clothes, would knit for grandkids and loved home cooking'. She had been diagnosed with Alzheimer's dementia in 2019, but had shown symptoms of the condition since 2016. Mrs Yates moved into residential care, at Priory House Care Home in Prestatyn, in October 2022, and 'seemed really happy' at the home for the first 12 months and enjoyed activities. She had been prescribed edoxaban, an anti-coagulant (blood thinner) which mitigated the risk of a stroke – she had been on thinners for several years. However, in October 2023, while monthly medication had arrived for patients at Priory House on October 18, Mrs Yates' had not. The community pharmacist was contacted and responded that they 'didn't have it yet', said Prio House director Frances Waltham. A daily medication Mrs Yates was now without since October 28, the care home made several requests (both before and after her running out of medication) to the pharmacist for the medication, but by as late as November 16 they had still not received it. A prescription had been sent to the pharmacist on November 16, ten days after the issue was last recorded as being raised. Mrs Yates' GP surgery, Healthy Prestatyn Iach, were not informed at the same time that she had been without medication. Mrs Yates suffered a stroke in December that year, which her family said lead to a 'distinct change and a downward spiral' and her transfer to Ysbyty Glan Clwyd. Dr Gordon Black, a general physician specialising in stroke treatment, said that they had noted Mrs Yates' 'right side weakness, aphasia, and unsafe swallow' in November – between her going without medication and her stroke. She was moved to a community hospital from Glan Clwyd, and then into St Chamond's in Prestatyn in June 2024 having had a paper tube fitted. Her son told the inquest she 'never spoke after that' and 'couldn't move her right side and was bedridden', adding that her 'quality of life completely changed beyond recognition'. READ MORE: 'Loving, caring' Rhuddlan mother will be 'hugely missed' Rhyl: What Dean Mears' life sentence and minimum term mean Dr Judah Eastwell, clinical lead GP at Healthy Prestatyn Iach, said that her receiving her medication when she had been supposed to in October 2023 'would have mitigated risks of stroke'. From November 2024, Mrs Yates had developed a chest infection and was now 'really jaundiced', but Welsh Ambulance Service determined admission to hospital was not necessary. By December, her blood tests showed deterioration of the liver, and an ultrasound scan showed a 'mass', believed to be cancerous, adjacent to the pancreas on her liver. It was decided not to proceed with an investigation into the cancer as this could have caused difficulties with her other health problems. In January, Mrs Yates developed a fever and 'chesty breathing', after which she was given antibiotics and died on January 2. Mr Gittins gave a narrative conclusion, and said: 'For a period of approximately 20 days from 28 October, 2023 due to a prescribing and dispensing error the deceased was not given her medication. 'Her condition deteriorated from the time of the stroke onwards resulting in her being immobile until her death at St Chamond's in Prestatyn. 'Her stroke in 2023 has more than minimally contributed to her death and it is probable that this would not have been the case if medication had been delivered.'
South Wales Guardian
2 days ago
- South Wales Guardian
Alzheimer's and Parkinson's charities identify new ways to reuse current drugs
Experts say that by repurposing drugs, they can 'increase the shots on target' at tackling the diseases. This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added. It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service. The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost. Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases. After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials. Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses. Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's. Trial results for the Alzheimer's trial are expected to be published later this year. Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process. 'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.' Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs. 'Getting multiple drugs that are targeting the disease is really important to us,' she said. 'Testing different types of drugs and getting as many shots on target is important.' She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process. 'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.' Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'. She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas. 'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies. 'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.' She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS. And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment. 'They showed for the very first time that we were able to alter the course of the disease. 'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.' Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker. 'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'
